Dangerous Drug: Bendamustine Hydrochloride(ben’ dah moos’ teen)
Treanda
PREGNANCY CATEGORY D
Drug Classes
Alkylating agent
Antineoplastic
Therapeutic Actions
Cytotoxic; alkylates DNA and RNA and inhibits several enzymatic processes, leading to cell death.
Indications
Treatment of chronic lymphocytic leukemia (CLL)
Treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 mo of rituximab therapy or a rituximab-containing regimen
Contraindications and Cautions
Contraindicated with known hypersensitivity to bendamustine or mannitol, pregnancy, lactation, moderate or severe hepatic impairment, severe renal impairment.
Use cautiously in patients with moderate renal impairment, mild hepatic impairment.
Available Forms
Single-use vials—25, 100 mg
Dosages
Adults
CLL: 100 mg/m2 IV over 30 min on days 1 and 2 of a 28-day cycle for up to 6 cycles; dosage may need to be lowered based on patient response and drug toxicity.
Non-Hodgkin lymphoma: 120 mg/m2 IV over 60 min on days 1 and 2 of a 21-day cycle for up to 8 cycles; dosage may need to be adjusted based on patient response.
Pediatric patients
Safety and efficacy not established.
Patients with hepatic or renal impairment
Use caution with mild dysfunction; do not use with moderate to severe hepatic dysfunction and severe renal dysfunction.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
